NAT-LENALIDOMIDE 15 MG
LENALIDOMIDE : 15 MG · DIN 02493888 · NATCO PHARMA (CANADA) INC
Health Canada status: MARKETED
What is NAT-LENALIDOMIDE?
NAT-LENALIDOMIDE 15 MG contains LENALIDOMIDE : 15 MG. It is listed in the Health Canada Drug Product Database under DIN 02493888, held by NATCO PHARMA (CANADA) INC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 01-Sep-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is NAT-LENALIDOMIDE used for?
Treatment of transfusion-dependent anemia due to Low- or Intermediate-1-risk MDS with 5q deletion; Multiple Myeloma in patients not eligible for stem cell transplant.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02493888 |
|---|---|
| Brand name | NAT-LENALIDOMIDE |
| Generic / active ingredient | LENALIDOMIDE : 15 MG |
| Manufacturer | NATCO PHARMA (CANADA) INC |
| Strength | 15 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L04AX04 LENALIDOMIDE |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 01-Sep-2021 |
| Original market date | 2021-09-01 00:00:00 |
How is it administered?
MDS: 10 mg daily Days 1-21 of 28-day cycle. MM: 25 mg daily Days 1-21 of 28-day cycle with dexamethasone. Adjust for renal impairment. Swallow whole; do not break/open.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly stated in the provided text snippet (section 11 is listed in TOC but content is missing).
How is it supplied?
21 count (3x7) blister packs (all strengths); 28 count (4x7) blister packs (5 mg and 10 mg strengths).
Contraindications
Pregnant women; women at risk of becoming pregnant; breastfeeding; hypersensitivity to lenalidomide, thalidomide, or pomalidomide; MDS patients with platelets < 50 x 10^9/L.
Warnings and precautions
Potential for human birth defects; neutropenia; thrombocytopenia; increased risk of DVT, PE, MI, and stroke; hepatotoxicity; anaphylaxis. Available only through RevAid program.
What can be used instead?
Other Canadian products sharing ATC code L04AX04 LENALIDOMIDE. 42 of 62 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-LENALIDOMIDE | 10 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02507943 |
| APO-LENALIDOMIDE | 15 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02507951 |
| APO-LENALIDOMIDE | 2.5 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02507927 |
| APO-LENALIDOMIDE | 20 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02507978 |
| APO-LENALIDOMIDE | 25 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02507986 |
| APO-LENALIDOMIDE | 5 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02507935 |
| JAMP LENALIDOMIDE | 10 MG | CAPSULE | JAMP PHARMA CORPORATION | MARKETED | DIN 02506157 |
| JAMP LENALIDOMIDE | 15 MG | CAPSULE | JAMP PHARMA CORPORATION | MARKETED | DIN 02506165 |
| JAMP LENALIDOMIDE | 2.5 MG | CAPSULE | JAMP PHARMA CORPORATION | MARKETED | DIN 02506130 |
| JAMP LENALIDOMIDE | 20 MG | CAPSULE | JAMP PHARMA CORPORATION | MARKETED | DIN 02506173 |
Who else supplies LENALIDOMIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. LENALIDOMIDE appears in 1872 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.